Interleukin 1 Receptor-Like 1 (IL1RL1) (AA 19-328) (Active) Protein

Details for Product No. ABIN2666553, Supplier: Log in to see
Protein Name
  • DER4
  • Fit-1
  • Ly84
  • ST2L
  • St2
  • St2-rs1
  • T1
  • T1/ST2
  • FIT-1
  • IL33R
  • ST2
  • ST2V
  • FIT1
  • interleukin 1 receptor-like 1
  • Il1rl1
  • IL1RL1
Protein Characteristics
AA 19-328
5
4
2
2
1
1
1
1
1
1
Origin
Human
17
7
Source
HEK-293
6
4
4
2
2
1
1
1
Protein Type
Recombinant
Biological Activity
Active
Application
Flow Cytometry (FACS), Immunofluorescence (IF)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Purity > 95 % , as determined by Coomassie stained SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Background IL-1RL1/ST2 was initially identified in stimulated Balc3T3 cells and is encoded by the IL-1RL1 gene that produces different isoforms by alternative splicing. In humans, four isoforms have been described: a membrane attached ST2L isoform and a soluble protein (sST2/ IL1RL-a) that lacks the transmembrane and cytoplasmic domains, which acts as a natural antagonist of IL-33. The other splice variants are ST2V and ST2LV. ST2V lacks the third immunoglobulin motif and C-terminal portion of ST2 and is mainly present in the gut whereas ST2LV does not have the transmembrane domain. The membrane isoform of ST2L (IL-1RL1) associates with IL-1 receptor accessory proteins (IL-1RAcP) to form the IL-33R. The interaction of IL-33 to its receptor activates NF-kB and MAP kinases and induces Th2 cytokines from in vitro polarized Th2 cells. In vivo, IL-33 promotes the expression of IL-4, IL-5, and IL-13. IL-33 acts as an inflammatory cytokine in Th2-type immune responses during asthma and atopic dermatitis. It is host-protective against helminth infections and reduces atherosclerosis by promoting Th2-type immune responses. Human aortic, coronary artery, and heart microvascular endothelial cells express mRNA for ST2L and sST2 isoforms, acting as a source for sST2 proteins. In fact, sST2 is considered as a prognostic biomarker in myocardial infarction and heart failure. In addition, sST2 has been associated with other human diseases including asthma with acute exacerbation, eosinophilic pneumonia, sepsis and trauma, and exacerbated idiopathic pulmonary fibrosis.
Molecular Weight The 550 amino acid recombinant protein has a predicted molecular mass of approximately 62 kDa. The DTT-reduced and non-reduced protein migrate approximately at 100 kDa and 200 kDa by SDS-PAGE. The predicted N-terminal amino acid is Lys.
Application Notes Optimal working dilution should be determined by the investigator.
Comment

Biological activity: ED50 = 15 - 90 ng/ml, corresponding to a specific activity of 1.1 - 6.6 x 104 units/mg , as determined by inhibition of D10.G4.1 cell proliferation induced by IL-33.

Restrictions For Research Use only
Format Liquid
Reconstitution For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.
Buffer 0.22 μm filtered protein solution is in 10 mM NaHPO4, 0.3M NaCl, and pH 7.2.
Handling Advice Avoid repeated freeze/thaw cycles.
Storage -20 °C
Storage Comment Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.
Background publications Demyanets, Kaun, Pentz, Krychtiuk, Rauscher, Pfaffenberger, Zuckermann, Aliabadi, Gröger, Maurer, Huber, Wojta: "Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature." in: Journal of molecular and cellular cardiology, Vol. 60, pp. 16-26, 2013 (PubMed).

Lin, Zhang, Zhao, Su, Deng, Pflugfelder, Li: "A novel interleukin 33/ST2 signaling regulates inflammatory response in human corneal epithelium." in: PLoS ONE, Vol. 8, Issue 4, pp. e60963, 2013 (PubMed).

Polumuri, Jayakar, Shirey, Roberts, Perkins, Pitha, Vogel: "Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 189, Issue 1, pp. 50-60, 2012 (PubMed).

Hayakawa, Hayakawa, Kume, Tominaga: "Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation." in: The Journal of biological chemistry, Vol. 282, Issue 36, pp. 26369-80, 2007 (PubMed).

Chackerian, Oldham, Murphy, Schmitz, Pflanz, Kastelein: "IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 4, pp. 2551-5, 2007 (PubMed).

Did you look for something else?